Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers 19-65 years old~* Females must be nonlactating and nonpregnant (negative serum pregnancy test at screening)and agree to practice effective birth control for at least 30 days after study completion~* Nonsmoker or no tobacco/nicotine use in previous 6 months~* Intact normal skin without obscuring tattoos, pigmentation or lesions~* Adequate venous access in upper extremities~* Normal vital signs, ECG, and labs or assessed by the Investigator as NCS~* Serum hemoglobin within site's normal range~* Negative drug and alcohol screen~* Able to make decisions and comply with study requirements~Exclusion Criteria:~* History of drug or alcohol abuse or positive drug and alcohol screen~* Abdominal surgery within the last 30 days~* Phenylketonuria~* Tobacco or nicotine use within previous 6 months~* Hypersensitivity or contraindication to ondansetron or other 5-HT3 receptor agonists~* Received ondansetron within 4 days prior to Day 1~* Known allergy to hyaluronidase or other ingredient in Hylenex recombinant~* Lower extremity edema~* Creatinine clearance \< 60 mL/min~* Dehydration (Grade 2 or higher)~* Hypersensitivity or contraindication to heparin~* Abnormal ECG with clinically significant QT prolongation or history of~* Female who is pregnant or breastfeeding~* Participation in a clinical trial (drug or device) within 30 days of enrollment~* Clinically significant medical history, major systemic disease, intercurrent illness, physical examination finding, or clinical laboratory test result that risks the subject's safety or interfere with interpretation of study results~* Not able to comply with study requirements

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Subcutaneous Administration (Type: EXPERIMENTAL): Ondansetron + Hylenex administered subcutaneously
- Oral Administration (Type: EXPERIMENTAL): Ondansetron administered orally
- Intramuscular Administration (Type: EXPERIMENTAL): Ondansetron administered intramuscularly
- Intravenous Administration (Type: EXPERIMENTAL): Ondansetron administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).